Max Healthcare Institute quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	2,569	2,135	+20.3%
EBITDA	711	575	+23.7%
EBITDA margin	27.7%	26.9%	+0.8 pts
Profit before tax	541	446	+21.3%
Net profit	414	491	−15.6%
EPS	₹4.26	₹5.05	−15.6%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	2,569	2,366	2,143	2,068	2,135	2,028	1,910	1,868	1,707	1,543	1,423	1,335	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	40.9	40.5	47.8	45.4	32.9	36.5	46.9	33.3	40.8	34.7	45.3	46.0
	2,610	2,407	2,191	2,113	2,168	2,064	1,957	1,902	1,748	1,578	1,468	1,381
	522	521	433	446	465	454	410	397	359	330	297	271
	−6.6	−7.8	6.2	−6.1	−0.3	−8.6	−0.7	−5.1	−10.2	−3.4	−1.8	−3.4
	399	388	340	340	338	338	316	305	284	270	242	231
	73.8	71.0	66.7	59.7	53.9	54.9	55.2	52.4	33.5	23.9	20.7	11.2
	138	132	123	111	108	104	101	97.5	84.2	76.9	70.3	61.0
	943	866	757	748	757	721	673	673	624	559	504	451
	2,069	1,970	1,726	1,700	1,722	1,664	1,554	1,519	1,375	1,256	1,132	1,021
	711	598	606	538	575	523	512	499	451	387	382	386
	574	467	483	427	467	419	411	402	366	311	311	325
Profit
	541	436	465	413	446	400	403	383	374	321	336	360
	0.0	0.0	0.0	−48.2	0.0	0.0	0.0	−73.6	0.0	0.0	0.0	0.0
	541	436	465	365	446	400	403	309	374	321	336	360
	95.3	82.5	58.6	46.0	10.3	96.4	72.1	91.0	91.7	81.4	73.6	75.1
	31.2	30.9	63.8	17.6	−55.6	−4.0	11.4	−20.9	0.2	3.7	10.6	−4.7
	126	113	122	63.6	−45.3	92.5	83.5	70.1	91.9	85.0	84.2	70.3
	414	323	342	301	491	308	319	239	282	236	252	289
	414	323	342	301	491	308	319	239	282	236	252	289
	7.9	−4.8	1.3	−0.1	0.0	−2.8	−0.1	−0.4	−2.3	−1.8	−0.9	−0.7
	422	318	343	301	491	305	319	238	280	235	251	289
	415	—	—	301	491	—	—	239	282	236	251	289
	−0.5	—	—	0.0	0.0	—	—	0.0	0.0	0.0	0.0	0.0
Per share
	₹4.26	₹3.32	₹3.52	₹3.10	₹5.05	₹3.17	₹3.28	₹2.46	₹2.90	₹2.43	₹2.59	₹2.98
	₹4.24	₹3.30	₹3.50	₹3.09	₹5.02	₹3.15	₹3.26	₹2.44	₹2.88	₹2.42	₹2.58	₹2.97
Other comprehensive income — detail
	7.9	−4.8	1.3	−0.1	0.0	−2.8	−0.1	—	—	—	—	—
	0.4	0.1	1.1	0.4	0.2	−3.5	−0.3	−0.2	−2.5	−2.2	−0.7	−0.4
	0.1	0.1	0.3	0.3	0.0	−0.7	−0.1	—	—	—	—	—
	—	—	—	—	—	—	—	−0.0	−0.2	−0.4	0.1	0.1
	10.2	−6.5	0.5	−0.1	−0.2	−0.0	−0.0	−0.2	−0.1	0.0	−0.1	−0.1
	2.6	−1.6	0.0	0.0	0.0	0.0	0.0	—	—	—	—	—
	423	—	—	301	491	—	—	238	280	235	251	289
	−0.6	—	—	0.0	0.0	—	—	0.0	0.0	0.0	0.0	0.0
Per share — as-filed variants
	₹4.26	₹3.32	₹3.52	₹3.10	₹5.05	₹3.17	₹3.28	₹2.46	₹2.90	₹2.43	₹2.59	₹2.98
	₹4.24	₹3.30	₹3.50	₹3.09	₹5.02	₹3.15	₹3.26	₹2.44	₹2.88	₹2.42	₹2.58	₹2.97
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	2,054	1,853	1,703	1,627	1,671	1,582	1,500	1,476	1,358	1,216	1,127	1,068
	79.9%	78.3%	79.5%	78.7%	78.2%	78.0%	78.6%	79.0%	79.5%	78.8%	79.2%	80.0%
Adjusted (ex-exceptional items) — derived
	541	436	465	413	446	400	403	383	374	321	336	360
	0.0	0.0	0.0	−48.2	0.0	0.0	0.0	−73.6	0.0	0.0	0.0	0.0
	414	323	342	341	491	308	319	296	282	236	252	289
	₹4.26	₹3.32	₹3.52	₹3.51	₹5.05	₹3.17	₹3.28	₹3.05	₹2.90	₹2.43	₹2.59	₹2.98

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MAXHEALTH₹851.15

Max Healthcare Institute Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAPOLLOHOSP FORTIS MEDANTA DRREDDY CIPLA SUNPHARMA DIVISLAB TORNTPHARMMcap ₹82,828 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	1,335.0	1,422.9	1,543.0	1,707.5	1,868.3	1,909.7	2,027.6	2,135.5	2,067.5	2,142.9	2,366.2	2,569.2
Other Income	46.0	45.3	34.7	40.8	33.3	46.9	36.5	32.9	45.4	47.8	40.5	40.9
Total Income	1,381.0	1,468.2	1,577.6	1,748.3	1,901.6	1,956.7	2,064.1	2,168.4	2,112.9	2,190.7	2,406.7	2,610.1
Expenses
+ Purchases of Stock-in-Trade	270.7	297.4	330.0	359.4	396.9	410.1	453.8	465.2	446.5	433.3	521.2	521.9
+ Changes in Inventories	-3.4	-1.8	-3.4	-10.2	-5.1	-0.7	-8.6	-0.3	-6.1	6.2	-7.8	-6.6
+ Employee Benefit Expense	230.7	241.8	270.2	283.6	304.6	315.6	338.1	338.3	340.5	340.3	388.2	399.3
+ Finance Costs	11.2	20.7	23.9	33.5	52.4	55.2	54.9	53.9	59.7	66.7	71.0	73.8
+ Depreciation & Amortisation	61.0	70.3	76.9	84.2	97.5	100.8	104.1	108.1	111.3	123.0	131.7	137.6
+ Other Expenses	451.2	503.9	558.8	624.1	672.8	673.1	721.4	757.1	748.4	756.7	866.2	943.1
Total Expenses	1,021.3	1,132.4	1,256.3	1,374.6	1,519.1	1,554.2	1,663.7	1,722.3	1,700.1	1,726.1	1,970.4	2,069.2
EBITDA	385.9	381.5	387.4	450.5	499.1	511.6	522.9	575.2	538.3	606.4	598.5	711.5
EBIT	324.9	311.2	310.5	366.4	401.6	410.8	418.8	467.1	427.1	483.4	466.8	573.9
Profit
PBT before Exceptional Items	359.7	335.7	321.3	373.7	382.5	402.5	400.4	446.0	412.8	464.6	436.3	540.9
+ Exceptional Items	0.0	0.0	0.0	0.0	-73.6	0.0	0.0	0.0	-48.2	0.0	0.0	0.0
Pretax Income	359.7	335.7	321.3	373.7	308.9	402.5	400.4	446.0	364.5	464.6	436.3	540.9
+ Current Tax	75.1	73.6	81.4	91.7	91.0	72.1	96.4	10.3	46.0	58.6	82.5	95.3
+ Deferred Tax	-4.7	10.6	3.7	0.2	-20.9	11.4	-4.0	-55.6	17.6	63.8	30.9	31.2
Tax Expense	70.3	84.2	85.0	91.9	70.1	83.5	92.5	-45.3	63.6	122.4	113.4	126.5
Net Income	289.3	251.5	236.3	281.8	238.8	319.0	308.0	491.3	300.9	342.2	323.0	414.5
+ Net Income — Continuing Ops	289.3	251.5	236.3	281.8	238.8	319.0	308.0	491.3	300.9	342.2	323.0	414.5
+ Other Comprehensive Income	-0.7	-0.9	-1.8	-2.3	-0.4	-0.1	-2.8	0.0	-0.1	1.3	-4.8	7.9
Total Comprehensive Income	288.7	250.7	234.5	279.5	238.4	318.9	305.2	491.3	300.9	343.5	318.2	422.4
Net Income to Common	289.3	250.7	236.3	281.8	238.8	—	—	491.3	300.9	—	—	414.9
Minority Interest	0.0	0.0	0.0	0.0	0.0	—	—	0.0	0.0	—	—	-0.5
Per Share
Basic EPS	2.98	2.59	2.43	2.90	2.46	3.28	3.17	5.05	3.10	3.52	3.32	4.26
Diluted EPS	2.97	2.58	2.42	2.88	2.44	3.26	3.15	5.02	3.09	3.50	3.30	4.24
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-0.1	-2.8	0.0	-0.1	1.3	-4.8	7.9
+ Items NOT to be Reclassified to P&L	-0.4	-0.7	-2.2	-2.5	-0.2	-0.3	-3.5	0.2	0.4	1.1	0.1	0.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-0.1	-0.7	0.0	0.3	0.3	0.1	0.1
+ Tax on Items NOT to be Reclassified — alt tag	0.1	0.1	-0.4	-0.2	-0.0	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-0.1	-0.1	0.0	-0.1	-0.2	-0.0	-0.0	-0.2	-0.1	0.5	-6.5	10.2
+ Tax on Items to be Reclassified	—	—	—	—	—	0.0	0.0	0.0	0.0	0.0	-1.6	2.6
Comprehensive Income — Owners of Parent	288.7	250.7	234.5	279.5	238.4	—	—	491.3	300.9	—	—	422.9
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	0.0	0.0	—	—	0.0	0.0	—	—	-0.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.98	2.59	2.43	2.90	2.46	3.28	3.17	5.05	3.10	3.52	3.32	4.26
Diluted EPS — Continuing Operations	2.97	2.58	2.42	2.88	2.44	3.26	3.15	5.02	3.09	3.50	3.30	4.24
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,067.7	1,127.3	1,216.4	1,358.2	1,476.5	1,500.3	1,582.3	1,670.6	1,627.2	1,703.4	1,852.8	2,053.9
Gross Margin %	79.98	79.23	78.84	79.55	79.03	78.56	78.04	78.23	78.70	79.49	78.30	79.94
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	359.7	335.7	321.3	373.7	382.5	402.5	400.4	446.0	412.8	464.6	436.3	540.9
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	-73.6	0.0	0.0	0.0	-48.2	0.0	0.0	0.0
Net Income Adj (tax-effected)	289.3	251.5	236.3	281.8	295.7	319.0	308.0	491.3	340.7	342.2	323.0	414.5
EPS Adj	2.98	2.59	2.43	2.90	3.05	3.28	3.17	5.05	3.51	3.52	3.32	4.26
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	971.8	971.9	971.9	972.1	972.1	972.1	972.2	972.2	972.8	973.1	973.2	973.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Max Healthcare Institute Q2 FY27 results (July–September 2026)

Filed with NSE on Friday, 30 October 2026 at 2:44 pm IST

Max Healthcare Institute (NSE: MAXHEALTH) reported its Q2 FY27 results (July–September 2026) on Friday, 30 October 2026 at 2:44 pm IST. Consolidated net profit was ₹415 crore, down 15.5% from ₹491 crore in Q2 FY26 and up 28.5% from ₹323 crore in Q1 FY27. Revenue from operations was ₹2,569 crore, up 20.3% year on year and up 8.6% from the previous quarter.

Q2 FY26 results (a year earlier): 14 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹415 Cr−15.5% vs Q2 FY26+28.5% vs Q1 FY27
Revenue from operations: ₹2,569 Cr+20.3% vs Q2 FY26+8.6% vs Q1 FY27
Operating margin (EBIT): 22.3%+0.5 pts vs Q2 FY26+2.6 pts vs Q1 FY27EBIT ₹574 Cr
EBITDA: ₹711 Cr+23.7% vs Q2 FY26+18.9% vs Q1 FY27margin 27.7%
Earnings per share (basic): ₹4.26−15.6% vs Q2 FY26+28.3% vs Q1 FY27
Net profit margin: 16.2%−6.9 pts vs Q2 FY26+2.5 pts vs Q1 FY27

Questions

What was Max Healthcare Institute's net profit in Q2 FY27?

Consolidated net profit was ₹415 crore, down 15.5% from ₹491 crore in Q2 FY26 and up 28.5% from ₹323 crore in Q1 FY27.

What was Max Healthcare Institute's revenue in Q2 FY27?

Revenue from operations was ₹2,569 crore, up 20.3% year on year and up 8.6% from the previous quarter.

What was Max Healthcare Institute's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹574 crore, a margin of 22.3%, against 19.7% in Q1 FY27 and 21.9% in Q2 FY26. EBITDA was ₹711 crore, 27.7% of revenue.

How were Max Healthcare Institute's Q2 FY27 results?

Revenue grew from a year earlier while net profit fell: revenue was up 20.3% at ₹2,569 crore, and net profit was down 15.5% at ₹415 crore. The operating margin was 22.3%, up 0.5 percentage points from 21.9% a year earlier. Against Q1 FY27, net profit was up 28.5% and revenue up 8.6%.

How has Max Healthcare Institute's profit changed over the last four quarters?

Net profit by quarter: ₹301 crore in Q3 FY26, ₹342 crore in Q4 FY26, ₹323 crore in Q1 FY27 and ₹415 crore in Q2 FY27. That is ₹1,381 crore over the four quarters, up 1.8% from ₹1,357 crore in the four quarters before. Revenue from operations: ₹2,068 crore, ₹2,143 crore, ₹2,366 crore and ₹2,569 crore.

When will Max Healthcare Institute announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

What was Max Healthcare Institute's EPS in Q2 FY27?

Basic earnings per share were ₹4.26, against ₹5.05 in Q2 FY26.

What was Max Healthcare Institute's net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹738 crore, down 7.7% from ₹799 crore in the same months a year earlier. Revenue from operations was ₹4,935 crore, up 18.6%.

When did Max Healthcare Institute announce its Q2 FY27 results?

On Friday, 30 October 2026 at 2:44 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 14 November 2025.

What is Max Healthcare Institute's net profit margin?

Max Healthcare Institute's net profit margin was 16.2% in Q2 FY27 (net profit as a share of revenue from operations), against 23.0% in Q2 FY26 (down 6.9 percentage points). For FY26 as a whole it was 17.2%.

What was Max Healthcare Institute's net profit in FY26?

Consolidated net profit was ₹1,442 crore in FY26 (April 2025–March 2026), up 34.1% from ₹1,076 crore in FY25. It was ₹1,051 crore in FY24 and ₹1,104 crore in FY23: up 30.7% over three years, 9.3% a year on average.

What was Max Healthcare Institute's revenue in FY26?

Revenue from operations was ₹8,373 crore in FY26 (April 2025–March 2026), up 19.1% from ₹7,028 crore in FY25. It was ₹5,406 crore in FY24 and ₹4,563 crore in FY23: up 83.5% over three years, 22.4% a year on average.

Where do these Max Healthcare Institute figures come from?

From Max Healthcare Institute's own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 30 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.